Fresh analysis suggests that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt traditional lifestyle regimens.
Findings released in a major medical journal points out that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs should be aware of the danger of fast rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass within about 18 months.
Weighing Treatments
The analysis, which looked at dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods.
Researchers emphasize that people who lose weight through dieting usually see a slower creep back—around 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Nutrition scientists propose the way of the injections is key to understanding the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making overeating far more likely."
A Chronic Disease?
The NHS recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the treatment is often life-long.
This opinion is supported by drug manufacturers, who state that the findings "underscore the persistent character of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have stopped the medication report a intense return of appetite.
"I experienced something activating and you're instantly starving," recalled an individual.
The struggle is worsened if individuals have not established lasting lifestyle or habit modifications during treatment.
Significant Use
Recent estimates indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle changes.
